Condition: Primary CNS Lymphoma (PCNSL) · Sponsor: NOBO Medicine
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
This description comes directly from the study's public registry record.
Hong Yul An · 02-6215-6200 · anhongyul@nobomedicine.com
Sukyung Je · 82-2-6215-6200 · sukyung.je@nobomedicine.com
Always discuss trial participation with your own doctor first.
| Kosin University Gospel Hospital | Busan, South Korea | Not Yet Recruiting |
| Chonnam National University Hwasun Hospital | Hwasun, South Korea | Not Yet Recruiting |
| Korea National Cancer Center | Ilsan, South Korea | Not Yet Recruiting |
| Seoul National University Bundang Hospital | Seongnam, South Korea | Not Yet Recruiting |
| Asan Medical Center | Seoul, South Korea | Not Yet Recruiting |
| Catholic univ of Yeouido St Mary's Hospital | Seoul, South Korea | Not Yet Recruiting |
| Korea University Anam Hospital | Seoul, South Korea | Not Yet Recruiting |
| Samsung Medical Center | Seoul, South Korea | Not Yet Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Ulsan University Hospital | Ulsan, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06737250